What is Optimed Research?
Founded by Dr. Donald McNeil, Optimed Research operates as a sophisticated national network dedicated to the execution of Phase II-IV clinical studies. The organization distinguishes itself through the integration of advanced cloud-based technology and real-time data capture systems, which streamline the complexities of trial management. By bridging the gap between sponsors, physicians, and patients, the firm facilitates a more efficient pathway for drug development. Their focus on high-acuity therapeutic areas such as CNS and immunology positions them as a critical partner for biopharmaceutical companies seeking to accelerate time-to-market for novel therapies while maintaining rigorous quality standards.
How much funding has Optimed Research raised?
Optimed Research has raised a total of $304K across 2 funding rounds:
Debt
$150K
Debt
$154K
Debt (2020): $150K with participation from PPP
Debt (2021): $154K led by PPP
Key Investors in Optimed Research
PPP
Public-Private Partnership
What's next for Optimed Research?
With the recent influx of capital, Optimed Research is well-positioned to enhance its technological capabilities and expand its footprint in the clinical research organization market. The strategic focus will likely center on optimizing trial efficiency through further digital transformation and potentially broadening its therapeutic reach. As the industry shifts toward decentralized and data-heavy trial models, the company's existing infrastructure provides a scalable foundation for future growth. Investors are closely monitoring how this late-stage financing will be deployed to capture additional market share and improve patient access to cutting-edge medical interventions.
See full Optimed Research company page
